| P50 | author | Ulrike Steckelings | Q55221665 |
| | Björn Dahlöf | Q47156424 |
| P2093 | author name string | Masatsugu Horiuchi | |
| | Masaki Mogi | |
| | Jun Iwanami | |
| | Li-Juan Min | |
| | Akiyoshi Ogimoto | |
| | Jitsuo Higaki | |
| | Fei Jing | |
| | Kana Tsukuda | |
| | Kousei Ohshima | |
| | Tomas Unger | |
| P2860 | cites work | Fetuin-null mice are protected against obesity and insulin resistance associated with aging. | Q51488607 |
| | Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? | Q54506199 |
| | A noninvasive computerized tail-cuff system for measuring blood pressure in mice | Q72210808 |
| | Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat | Q72709558 |
| | Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells | Q73054117 |
| | TNFalpha and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells | Q74156348 |
| | Tumor necrosis factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic beta cells | Q77932870 |
| | Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue | Q79696160 |
| | Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance | Q83069122 |
| | Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. | Q41431151 |
| | Tumour necrosis factor-alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway. | Q42027895 |
| | Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential | Q43253857 |
| | Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells | Q43646691 |
| | 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells | Q43785533 |
| | Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice | Q44810052 |
| | Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. | Q44816727 |
| | AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice. | Q46011143 |
| | Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy | Q46388306 |
| | Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance | Q46406520 |
| | Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation | Q46578517 |
| | Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs | Q46599371 |
| | Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models | Q46813413 |
| | Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes | Q46917054 |
| | Ventromedial hypothalamic stimulation enhances peripheral glucose uptake in anesthetized rats. | Q48661229 |
| | Inflammation and insulin resistance | Q22241893 |
| | International union of pharmacology. XXIII. The angiotensin II receptors | Q28138041 |
| | IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance | Q29619774 |
| | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 |
| | Adipokines in inflammation and metabolic disease | Q29620456 |
| | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 |
| | Identification and characterization of a functional mitochondrial angiotensin system | Q30427934 |
| | Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice | Q30433043 |
| | Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. | Q31126656 |
| | Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation | Q31806569 |
| | Involvement of bradykinin and nitric oxide in leptin-mediated glucose uptake in skeletal muscle. | Q31836112 |
| | Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 |
| | Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships | Q33264567 |
| | Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 |
| | Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 |
| | Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. | Q34541234 |
| | Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 |
| | Angiotensin AT2 receptors: cardiovascular hope or hype? | Q35045801 |
| | The many faces of PPARgamma | Q36344625 |
| | The physiology of a local renin-angiotensin system in the pancreas | Q36705812 |
| | The role of peroxisome proliferator‐activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus | Q37150550 |
| | Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency | Q37175466 |
| | Angiotensin II and the development of insulin resistance: implications for diabetes | Q37371106 |
| | The angiotensin AT2 receptor in left ventricular hypertrophy | Q37786172 |
| | A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity | Q38361522 |
| | Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control | Q39905953 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | insulin resistance | Q1053470 |
| | type 2 diabetes | Q3025883 |
| | preproinsulin | Q7240673 |
| P304 | page(s) | e48387 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation | |
| P478 | volume | 7 | |